| Name | Title | Contact Details |
|---|---|---|
Chris Akeroyd |
Senior Vice President, Chief Information Officer | Profile |
Seqirus, part of the CSL Group, is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, the two businesses joined forces to create Seqirus, now the second largest influenza vaccine company in the world. With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus has a workforce of over 2,000 employees, significant manufacturing capacity and a commercial presence in over 20 countries. In Australia and New Zealand, Seqirus markets a comprehensive range of vaccines and speciality pharmaceutical products. It also manufactures products of national significance for Australia, including antivenoms and Q fever vaccine, and supplies diagnostic reagents in the Australasia region. Seqirus cold-chain logistics business ensures the integrity of CSL products, as well as those of our customers, as they are safely delivered across Australia.
Medefil Inc is a Glendale Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Abacus Medicine Group creates better access to medicine. We help life-critical medicines become more widely available.
We providing a continuum of care through our three programs: Foster Care and Adoption Program, Residential Treatment Program, and Child Development Center.
Sequella is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.